Corrections
We correct in the open. Every change to a published article is logged here, with a date.
The Vital Record treats corrections as first-class, public records. We do not silently edit published stories. When a factual error is found, the original text is preserved in the page’s history and a dated correction note is appended.
We use three levels:
- Clarification — wording improved; no factual change.
- Correction — a factual error fixed.
- Retraction — a claim that cannot be supported; the article stays online with a prominent retraction notice so the record is honest.
Log
AbbVie Opens Pivotal Gene Therapy Trial for Diabetic Retinopathy
Trial described as targeting proliferative diabetic retinopathy throughout; NCT07592273 (NAAVIGATE) enrolls patients with moderately severe or severe nonproliferative DR (NPDR) without CI-DME. Primary endpoint also wrong (article: BCVA change at 24 months; registry: ≥2-step DRSS improvement at week 52). Geographic scope overstated: article lists US/Europe/Asia-Pacific; registry lists US and Puerto Rico only.
At 25 Years, Lifestyle Cuts Multimorbidity Risk; Metformin Does Not
Multimorbidity defined as '2+ of 8 conditions' listing 8 diseases; JAMA source defines it as 2+ of 15 prevalent CMS Chronic Condition Data Warehouse conditions. HR 0.57 also misframed as diabetes onset reduction; source attributes it to dyads of the costliest conditions, not diabetes incidence. Per-arm Ns off: lifestyle n=380 (source: 385), metformin n=390 (source: 385).
Triple-Drug Regimen Halves Progression Risk in Hard-to-Treat Myeloma
Named the experimental regimen as mezigdomide + elotuzumab + dexamethasone (MEd) but SUCCESSOR-2 (NCT05552976) tests mezigdomide + carfilzomib + dexamethasone (MeziKD) vs Kd; also wrong AE rates (article: 78% MeziKD / 69% Kd; source: 84% / 56%), infections (21% vs 34%), neutropenia (67% vs 61%).
What SUCCESSOR-2 Tells Us About the CELMoD Era in Myeloma
Editorial identifies the SUCCESSOR-2 experimental regimen as mezigdomide + elotuzumab + dexamethasone; the actual regimen is mezigdomide + carfilzomib + dexamethasone (MeziKD).
AI Grading Cuts False Referrals by 45 Points in Diabetic Macular Edema Screening
Sensitivity for DME referral stated as 97.1% in both arms; JAMA source (ChiCTR2300075087) reports 100.0% (95% CI, 100.0%–100.0%) in both the AI-assisted and standard grading groups.
Headline previously referred to 'the First FDA-Authorized Autonomous AI Cardiologist,' implying a finished product; ARPA-H describes ADVOCATE as a funding program to develop such a system; headline corrected to remove the 'cardiologist' characterization and add 'Fund Development of.'
The Cochrane uterotonic NMA (122 RCTs, 121,931 women) was described without attribution to its actual source publication (Gallos et al., Cochrane Database of Systematic Reviews, DOI 10.1002/14651858.CD011689.pub4, 2025); it is a separate Cochrane paper cited within Lancet Paper 2 (Prevention), not Lancet Paper 3 (Treatment).
EMPACT-MI: Empagliflozin Falls Short on Primary Endpoint After Acute Heart Attack
Trial sponsors Boehringer Ingelheim and Eli Lilly and Company were not disclosed in the article body; disclosure added to the Trial Design section (confirmed: NEJM PMID 38587237 and ClinicalTrials.gov NCT04509674).
Headline stated SGE 'Resolves Nearly All Uncertain Variants'; the preprint reports data 'provide strong functional evidence to support variant classification' — a contribution to a multi-step process, not a standalone resolution; headline corrected to 'Characterizes Nearly All Variants... Supporting Future Clinical Classification.'
AI Pathology Models Pass Lab Tests But Stumble Across Hospitals, New Benchmark Finds
Article cited a top Robustness Index score of 0.928 for the highest-ranked model; that figure is from the GitHub leaderboard composite, not the paper's primary reported results (which show ~0.861 averaged across all four datasets).
FDA Classifies J&J Cerenovus Brain Coil Recall as Class I After Patient Death and Four Injuries
Article described the CEREPAK as a Class III PMA device; FDA records confirm it is a Class II device cleared via 510(k) pathway (K220040).
CDC Opens Emergency Operations Center as Screwworm Infestations Spread Across Texas and New Mexico
Article reported four cattle and one goat in Texas as of June 9; confirmed USDA data shows four cattle and two goats (one in Edwards County, one in Gillespie County).
Article listed the Ad26.ZEBOV/MVA-BN-Filo regimen (Zabdeno/Mvabea) as a currently licensed vaccine; the European Commission withdrew its marketing authorisation in May 2026 — it is no longer licensed.
A Race Against a Virus We Have No Licensed Weapon to Fight
Editorial described only the rVSV-BDBV vaccine candidate (7–9 months to trial readiness) without noting the ChAdOx1 Bundibugyo candidate (Oxford/Serum Institute) identified by the same WHO expert group as potentially trial-ready in 2–3 months.
The Bundibugyo Lineage Is a Warning, Not Just a Diagnosis
Article cited '52 in 2012' for the Bundibugyo Isiro outbreak; WHO DON records and authoritative summaries report 36-38 laboratory-confirmed cases from that outbreak — the 52 figure derives from a specific epidemiological study cohort, not the WHO-certified final total.
Ecopipam Cuts Tourette Relapse Risk by Half in Phase 3 D1AMOND Withdrawal Trial
Article reported relapse rates without defining relapse; per NCT05615220 the D1AMOND relapse definition required loss of >=50% of YGTSS-TTS improvement gained during open-label plus rescue medication use or hospitalization — a critical methodological detail absent from the original text.
FDA Issues First Generic Animal-Drug EUA Against New World Screwworm
The headline and lead called the authorization the 'first-ever generic animal drug EUA,' dropping the FDA's qualifier. Per the FDA, it is the first generic animal drug authorized for use against New World screwworm; earlier NWS animal-drug authorizations covered branded products. Headline and lead corrected to restore the 'against New World screwworm' scope.
Moringa-Supplement Salmonella Outbreaks Total 147 Cases Across Three CDC Investigations
The headline and lead presented a combined '137 cases / 39 hospitalizations' total attributed to the CDC. CDC published no combined figure, and the sum of the three cited outbreak investigations (119+18+10 cases; 32+7+3 hospitalizations) is 147 cases and 42 hospitalizations — the original omitted the 10-case, 3-hospitalization Rosabella outbreak. Corrected to 147/42 and reframed as The Vital Record's own tally of CDC's separate outbreak pages, not a CDC-published total.
The dek and body stated that DNMT3A and TP53-LOF mutations 'did not respond' to sleep and exercise. Per the Nature paper, TP53 (Trp53)-LOF was a non-responder only on the clone-expansion endpoint; sleep and exercise did reduce TP53-LOF-driven atherosclerosis (alongside JAK2 and TET2), the study's clinically important cardiovascular outcome. DNMT3A was the only mutation that responded to neither. Corrected to distinguish the two endpoints and restore the omitted atherosclerosis finding.
Roche Terminates Phase 3 SKYSCRAPER-15 Tiragolumab Trial in Resected NSCLC, Deepening TIGIT Setbacks
Article described SKYSCRAPER-06 as a trial in 'advanced gastric or gastroesophageal junction cancer'; multiple primary sources (PubMed DOI:10.1001/jamaoncol.2024.4905, Lancet Oncology, ASCO Post) confirm SKYSCRAPER-06 (NCT04294810) was a Phase 3 trial in first-line advanced non-squamous NSCLC comparing tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab and chemotherapy; indication corrected.
Original title stated 'While Adults Stay Protected'; Cao lab preprint (DOI:10.64898/2026.06.05.730251) limits adult protection to those with ancestral-strain SARS-CoV-2 imprinting—adults exposed only to Omicron subvariants are described as 'weakly imprinted' and would not retain equivalent protection; title qualified to specify ancestral exposure.
DEK stated 'eight months after a Refuse-to-File stumble'; the article body itself records the RTF date as February 3, 2026, which is approximately four months before the June 18 VRBPAC meeting—not eight; corrected to 'four months'.
Investigational Once-Weekly HIV Pill Meets Primary Endpoints in Both Phase 3 ISLEND Trials
Article described the drug as 'Merck's islatravir-based regimen' without naming lenacapavir (Gilead's capsid inhibitor co-drug); ClinicalTrials.gov (NCT06630286, NCT06630299) titles the regimen 'Islatravir/Lenacapavir' and lists Gilead Sciences as primary sponsor; article updated to name both drugs and both companies.
Aficamten Beats Metoprolol on Exercise Capacity in Phase 3 Head-to-Head Trial for Obstructive HCM
DEK and body claimed superiority 'across every/all key pre-specified secondary endpoints'; NEJM primary paper (DOI:10.1056/NEJMoa2504654) explicitly states left ventricular mass index—a registered secondary endpoint—did not differ significantly between groups; corrected to five of six pre-specified secondary endpoints.
A First-Line Challenger: What MAPLE-HCM Means for the Clinic
SEQUOIA-HCM described as a '28-week placebo-controlled trial'; ClinicalTrials.gov NCT05186818 and NEJM DOI:10.1056/NEJMoa2401424 both confirm the double-blind treatment period was 24 weeks; corrected to 24-week.
Original headline read 'Nine-State Cluster'; CDC and FDA primary sources confirm confirmed cases span three states (Maryland, New York, Virginia) and the recall distribution covers five states plus DC—no source supports a nine-state figure; headline corrected to 'Three-State Outbreak'.
Article stated 'not found in the United States since 1966' and 'first re-emergence since 1966'; New World Screwworm re-emerged in the Florida Keys from September 2016 through March 2017, killing approximately 135 endangered Key deer before eradication; headline, dek, and body corrected to specify 'mainland' and acknowledge the 2016–17 Florida Keys episode.
Article grouped Candida albicans under 'bacteremic pathogens'; Candida albicans is a fungus, not a bacterium—the correct clinical terms are candidemia or fungemia, not bacteremia; collective term corrected to 'bloodstream pathogens'.
A leaderboard-topping LLM still botches potassium dosing in a preprint
An earlier headline and lede called GPT-5-Chat “leaderboard-topping.” The preprint describes it as a model that appears on the MedAgentBench leaderboard, not one that tops it — that benchmark is in fact led by other models. The wording was changed to “leaderboard-listed.” Flagged by the post-publication verification pass.
FDA labels BD Pyxis cabinet recall Class I after fingerprint-scanner fault
An earlier version described the recall as Class I, the FDA's most serious tier. The FDA recall database lists both records (Z-2298-2026 and Z-2297-2026) as Class II; the Class I label applies to the cabinet's device regulatory category, not to this recall. The headline, standfirst, chart and text were corrected, and the November 2024 warning-letter figures were attributed to MedTech Dive's reporting. Flagged by the post-publication verification pass.